STOCK TITAN
  1. Home
  2. News
  3. MTEM

Molecular Templates Inc - MTEM STOCK NEWS

Welcome to our dedicated news page for Molecular Templates (Ticker: MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Molecular Templates's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Molecular Templates's position in the market.

News
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Rhea-AI Summary
Molecular Templates, Inc. announces positive interim data on MT-6402, a novel therapy targeting PD-L1 in advanced solid tumors. The drug shows promising results in head and neck cancer patients, with durable partial responses and unique pharmacodynamic effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
clinical trial
-
News
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Molecular Templates, Inc. reports financial results for Q4 and full year 2023, highlighting positive clinical data for MT-6402 and MT-8421, along with a recent private placement. The company also discloses a terminated collaboration with Bristol-Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Rhea-AI Summary
Molecular Templates, Inc. (MTEM) secures $9.5 million through a securities purchase agreement with healthcare investors. The financing involves the issuance of shares and warrants at $2.60 per share to fund clinical studies and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
News
Molecular Templates, Inc. Provides Interim Update
Rhea-AI Summary
Molecular Templates, Inc. announces positive updates on its oncology programs including monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer and unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in an ongoing phase I study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
none
-
News
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Molecular Templates, Inc. (MTEM) will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The conference will feature a virtual presentation from 9:20am to 9:50am Eastern Time. The company will also be available for one-on-one meetings, and the webcast can be accessed through their corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Molecular Templates, Inc. (Nasdaq: MTEM) reported Q3 2023 financial results and business updates, highlighting initiation of expansion study with MT-6402 and phase I study for MT-8421 and MT-0169. The company continues to demonstrate novel mechanisms of action and single agent activity in heavily relapsed/refractory patients, with a focus on preclinical activities related to Bristol Myers Squibb collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
earnings
News
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
Rhea-AI Summary
Molecular Templates has announced the dosing of the first patient in a Phase 1 clinical trial for MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors. The study aims to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial will enroll adult patients with tumors where CTLA-4 inhibitors have shown benefit and other select tumor types. Approximately 24-30 patients are expected to enroll in the dose escalation phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
clinical trial
-
News
Molecular Templates to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Molecular Templates, Inc. (Nasdaq: MTEM) will be participating in several upcoming investor conferences. The UBS Biopharma Conference will take place on November 8-9, 2023, at The Fontainebleau Hotel in Miami, FL. The Stifel Annual Health Care Conference will be held on November 15, 2023, at the Lotte New York Palace Hotel in New York, NJ, with a live presentation and one-on-one meetings. The Evercore ISI 6th Annual HealthCONx Conference will occur on November 28-30, 2023, at the Kimpton Epic Hotel in Miami, FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
conferences
-
News
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
Rhea-AI Summary
Molecular Templates appoints Dr. Maurizio Voi as Chief Medical Officer, bringing extensive oncology drug development experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
management
News
Molecular Templates Announces 1-for-15 Reverse Stock Split
Rhea-AI Summary
Molecular Templates, Inc. (Nasdaq: MTEM) has announced a 1-for-15 reverse stock split of its common stock. The reverse stock split will take effect on August 11, 2023, and the company's common stock will begin trading under a new CUSIP number on August 14, 2023. The reverse stock split is intended to increase the per share trading price and regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
Stock MTEM logo
Molecular Templates Inc

Nasdaq:MTEM

MTEM Rankings

#5364 Ranked by Market Cap
#3964 Ranked by Stock Gains
N/A Ranked by Dividends

MTEM Stock Data

12.44M
3.28M
3.96%
58.79%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About MTEM

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.